Abstract
Background: Ketamine has been shown to produce a rapid and robust antidepressant effect. Though numerous routes of administration have been studied, subcutaneous (SC) has proven to be a convenient and cost-effective route making its use particularly relevant in developing countries. Here we provide a systematic review covering the use of SC racemic ketamine and esketamine in depression, including its efficacy, safety and tolerability. Methods: A systematic literature search was carried out, from inception through March, 2021, using PubMed/MEDLINE, EMBASE and Web of Science, with no limits of language. After identifying 159 potentially relevant articles, 12 articles were selected after applying our inclusion/exclusion criteria. These comprised two randomized clinical trials, five case-reports and five retrospective studies. Given the small number of studies found and their heterogeneous nature, a meta-analysis was not considered appropriate. Here we provide a synthesis of these data including participant characteristics, dose range, efficacy, safety/ tolerability. Risk of bias was accessed using the Cochrane risk of bias tool. Results: SC Ketamine was administered to unipolar and bipolar patients a single or multiple doses, week...Continue Reading
References
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1994·Pain·M BackonjaM Zimmermann
Oct 1, 1995·Journal of Pain and Symptom Management·S MercadanteR Serretta
Feb 28, 1998·Journal of Traumatic Stress·J D BremnerC M Mazure
Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Nov 3, 2005·Psychological Assessment·Alan Shafer
Aug 9, 2006·Archives of General Psychiatry·Carlos A ZarateHusseini K Manji
Aug 1, 1975·Neuroscience Letters·W V WeberS R Jawalekar
Jul 22, 2009·PLoS Medicine·Alessandro LiberatiDavid Moher
Jan 5, 2011·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Mihan J JavidAmir Keshvari
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Apr 21, 2012·Biological Psychiatry·Carlos A ZarateIrving W Wainer
Aug 3, 2012·The American Journal of Psychiatry·Cristina CusinMaurizio Fava
May 21, 2013·The International Journal of Neuropsychopharmacology·Diogo R LaraLuciano R Munari
Aug 29, 2013·The American Journal of Psychiatry·James W MurroughSanjay J Mathew
Nov 14, 2013·Anesthesiology and Pain Medicine·Mihan J JavidZahra Khazaeipour
Feb 11, 2014·Biological Psychiatry·Veronica GálvezColleen K Loo
Jan 27, 2015·Psychosomatics·Alana IglewiczScott A Irwin
Dec 29, 2015·Biological Psychiatry·Jaskaran B SinghLuc Van Nueten
Mar 31, 2016·Acta Psychiatrica Scandinavica·C K LooP Glue
Jul 26, 2017·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Duncan GeorgeColleen K Loo
Aug 2, 2017·The Lancet. Psychiatry·Brooke ShortColleen K Loo
Nov 28, 2017·World Neurosurgery·Michael M McDowellRobert M Friedlander
Oct 5, 2018·Molecular Psychiatry·Maurizio FavaGeorge I Papakostas
Mar 30, 2019·The American Journal of Psychiatry·Jennifer L PhillipsPierre Blier
Apr 18, 2019·The Journal of Clinical Psychiatry·Joshua D RosenblatRoger S McIntyre
May 22, 2019·The American Journal of Psychiatry·Vanina PopovaJaskaran B Singh
Jun 6, 2019·JAMA Psychiatry·Ella J DalyJaskaran B Singh
Feb 23, 2020·European Archives of Psychiatry and Clinical Neuroscience·Gustavo C LealLucas C Quarantini
Mar 19, 2020·Palliative Medicine·Matheus Ghossain BarbosaAndrea Parolin Jackowski
Jul 9, 2020·Journal of Psychopharmacology·Lorena Catarina Del SantJair de Jesus Mari
Oct 6, 2020·Journal of Affective Disorders·Rodrigo Simonini DelfinoAcioly Luiz Tavares Lacerda
Oct 7, 2020·Journal of Affective Disorders·Anees BahjiCarlos A Zarate
Oct 20, 2020·Revista de psiquiatrí́a y salud mental·Victor Augusto Rodovalho FavaHugo Cogo-Moreira
Nov 25, 2020·International Clinical Psychopharmacology·Fabio Lopes RochaDébora Pereira Thomaz
Jan 12, 2021·Journal of Psychopharmacology·Ana C LuccheseSergio B Andreoli